Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Dexamethasone + OPN-6602 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone | ||
OPN-6602 | OPN6602|OPN 6602 | CBP/p300 inhibitor 13 | OPN-6602 is a small molecule inhibitor of EP300 (p300) and CBP (CREBBP), which downregulates IRF4 and MYC, potentially inhibiting tumor growth (Cancer Res (2024) 84 (6_Supplement): 660). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06433947 | Phase I | OPN-6602 Dexamethasone + OPN-6602 | Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |